Seizure : the journal of the British Epilepsy Association
-
Multicenter Study
Development and validation of a seizure prediction model in critically ill children.
Electrographic seizures are common in encephalopathic critically ill children, but identification requires continuous EEG monitoring (CEEG). Development of a seizure prediction model would enable more efficient use of limited CEEG resources. We aimed to develop and validate a seizure prediction model for use among encephalopathic critically ill children. ⋯ Despite inherent variability between centers, a model developed using multi-center CEEG data and few readily available variables could guide the use of limited CEEG resources when applied at a single center. Depending on CEEG resources, centers could choose lower cut-off points to maximize identification of all patients with seizures (but with more patients monitored) or higher cut-off points to reduce resource utilization by reducing monitoring of lower risk patients (but with failure to identify some patients with seizures).
-
Multicenter Study
Efficacy of intravenous lacosamide as an add-on treatment in refractory status epilepticus: a multicentric prospective study.
Treatment of status epilepticus (SE) has not changed in the last few decades, benzodiazepines plus phenytoin or valproate being the most common treatment. Once this first and second line treatment has failed SE is considered refractory (RSE). This study aimed to assess the efficacy and tolerability of intravenous (iv) lacosamide (LCM) in RSE. ⋯ LCM might be a fast, effective and safe add-on treatment in RSE.
-
Multicenter Study Comparative Study Clinical Trial
An open-label, add-on study of pregabalin in patients with partial seizures: a multicenter trial in Greece.
Pregabalin efficacy and safety as an adjunctive treatment for partial seizures was evaluated using an open-label, flexible-dose. ⋯ The efficacy and side-effect profile of pregabalin were similar to previous pregabalin double-blind, controlled studies. Additionally, pregabalin, as an add-on treatment for partial epilepsy, exhibits significant anti-anxiety properties.
-
Multicenter Study
Efficacy and safety of levetiracetam in clinical practice: results of the SKATE trial from Belgium and The Netherlands.
Aim of the study was to assess the efficacy and safety of levetiracetam as add-on treatment in patients with partial-onset epilepsy in clinical practice. ⋯ Levetiracetam is effective and safe as add-on treatment for partial-onset seizures in clinical practice.
-
Multicenter Study Comparative Study Clinical Trial
An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
The novel antiepileptic drug (AED) levetiracetam (LEV, Keppra) is indicated as adjunctive therapy for partial epilepsy. The primary aim of this study was to measure the safety and tolerability of LEV individualised dosing in a heterogeneous refractory epilepsy population. ⋯ LEV was well tolerated, as evidenced by limited adverse event reporting and the high retention rate, and appeared effective in both generalised and partial epilepsy.